Akil Merchant is an Oncology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
127 S San Vicente Blvd Ste A-9102
Los Angeles, CA 900483311
Telephone
310-423-0161Registry record last updated 5 Apr 2019.
Clinical trials
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
Sponsor: University of Southern California
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202532 payments$58,281openpaymentsdata.cms.gov ↗
- Genmab U.S., Inc.Program year202510 payments$12,530openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
57.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor30.5%Valacyclovir100%Part D<11 patientsShort-acting sulfonamides27.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsDermatology
22%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22%Acyclovir100%Part D<11 patientsMetabolism & gastrointestinal
20.3%Serotonin-3 Receptor Antagonist20.3%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Spatially resolved, single cell biomarkers of B cell lymphoma
Cedars-Sinai Medical Center
FY2026$509,732R01CA266544 - Spatially resolved, single cell biomarkers of B cell lymphoma
Cedars-Sinai Medical Center
FY2025$624,093R01CA266544 - Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2
Cedars-Sinai Medical Center
FY2024$989,284U54CA260591
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”